

# Contents

<b>Preface</b>	<b>v</b>
<b>Abbreviations</b>	<b>vi</b>
<b>1. Diabetes prevention</b>	<b>1</b>
The Da Qing IGT and diabetes study	2
Diabetes Prevention Program (DPP)	4
Study TO Prevent Non-Insulin-Dependent Diabetes Mellitus (STOP-NIDDM)	6
XENical in the prevention of Diabetes in Obese Subjects (XENDOS)	8
Diabetes REduction Assessment with ramipril and rosiglitazone Medication (DREAM)	10
Indian Diabetes Prevention Programme (IDPP)	12
Nateglinide And Valsartan in IGT Outcomes Research (NAVIGATOR)	14
National Health And Nutrition Examination Survey (NHANES)	16
Anglo–Danish–Dutch study of Intensive Treatment In peOple with screeN-detected diabetes in primary care (ADDITION)	18
<b>2. Glucose control</b>	<b>21</b>
Pancreatic extracts in the treatment of diabetes mellitus	22
Diabetes Control and Complications Trial (DCCT)	24
Diabetes Audit and Research in Tayside Scotland/Medicines MOnitoring unit (DARTS/MEMO)	26
A Diabetes Outcome Progression Trial (ADOPT)	28
Risk of hypoglycaemia in types 1 and 2 diabetes	30
Survival as a function of HbA <sub>1c</sub> in people with type 2 diabetes	32
Diabetes therapy Utilization: Researching changes in HbA <sub>1c</sub> , weight and other factors Through Intervention with exenatide ONce weekly (DURATION)	34
DPP-4 inhibitors for treatment of type 2 diabetes mellitus	36
<b>3. Glycaemic interventions in CV disease</b>	<b>39</b>
Diabetes mellitus Insulin-Glucose infusion in Acute MI (DIGAMI)	40
Effect of a multifactorial intervention on CV morbidity in type 2 diabetes (STENO-2)	42
PROspective pioglitAzone Clinical Trial In macroVascular Events (PROACTIVE)	44
Effect of rosiglitazone on the risk of MI and death from CV causes	46
Action to Control CardiOvascular Risk in Diabetes (ACCORD)	48
United Kingdom Prospective Diabetes Study 10-year follow up (UKPDS 80)	50
Veterans Affairs Diabetes Trial (VADT)	52
Liraglutide Effect and Action in Diabetes (LEAD) programme	54
UKPDS 34	56

<b>4. Hypertension and diabetes</b>	<b>59</b>
Action in Diabetes and Vascular disease: preterAx and diamicroN modified-release Controlled Evaluation (ADVANCE)	60
<b>5. Dyslipidaemia and diabetes</b>	<b>63</b>
Heart Protection Study (HPS)	64
Atorvastatin in Factorial with omega-3 EE90 RR in Diabetes (AFORRD)	66
<b>6. The metabolic syndrome</b>	<b>69</b>
Role of insulin resistance in human disease	70
The metabolic syndrome: a new worldwide definition	72
<b>7. Obesity and diabetes</b>	<b>75</b>
Weight gain as a risk factor for clinical diabetes in women	76
Weight gain as a risk factor for clinical diabetes in men	78
Effect of surgical management of obesity on health outcomes in diabetes	80
Atkins, Traditional, Ornish, Zone (A TO Z) weight loss study	82
Surgical Treatment And Medications Potentially Eradicate Diabetes Efficiently (STAMPEDE)	84